Vaxart creates two new board committees, appoints members

Vaxart, Inc.

On Aug 21, 2026, board formed Clinical and Regulatory Affairs Committee and Stockholder Engagement Committee.
Dr. James B. Breitmeyer chairs Clinical/Regulatory; Dr. David Wheadon also appointed as member.
W. Mark Watson named Interim Chair of Stockholder Engagement Committee; Steven Lo also a member.
New director to chair Stockholder Engagement Committee per July 1, 2026 Cooperation Agreement.
Committees oversee clinical/regulatory programs and stockholder relations respectively.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.